Evofem Biosciences, Inc.: Evofem Biosciences (EVFM) is developing Amphora®, a Multipurpose Vaginal pH Regulator (MVP-R) and non-hormonal, on-demand, woman-controlled vaginal gel for birth control and the prevention of urogenital acquisition of certain STIs. In December 2018, the Company reported positive top-line data from its confirmatory Phase 3 study in ~1400 women in the US; anticipates a 2H19 NDA submission, with a potential US launch in 2020. Secured $30M strategic investment from PDL BioSciences (PDLI) in April 2019 for 6.7M shares at $4.50 (26% premium to prior day close) and 25% warrant coverage. Second tranche of financing up to $50M expected to close on or before June 10, 2019.
Based in...
United Kingdom, USA
Clinical Stage
Phase III
Disease Space
Men's Health, Women's Health
Public, USA
Market Cap
100MM - 500MM
12400 High Bluff Drive
Suite 600
San Diego, CA 92130
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.